Marijuana effects and behavioral contingencies.

Rw, Foltin; Mw, Fischman; Mj, Nellis; Dj, Bernstein; Mr, Ruiz; Jv, Brady

doi:10.1037/e468282004-001

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Participants smoked either a placebo or a cannabis cigarette, using the Foltin uniform puff procedure (inhalation for 5 s, followed by a 10-s breath-hold and exhalation, with a 45-s wait between puffs), 6 under supervision in a ventilated room. Participants completed an average of four puffs per cigarette.…”

Section: Methodsmentioning

confidence: 99%

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

Corey–Bloom

Wolfson

Gamst

et al. 2012

CMAJ

177

145

View full text Add to dashboard Cite

Research CMAJBackground: Spasticity is a common and poorly controlled symptom of multiple sclerosis. Our objective was to determine the short-term effect of smoked cannabis on this symptom. Methods:We conducted a placebo-controlled, crossover trial involving adult patients with multiple sclerosis and spasticity. We re cruited participants from a regional clinic or by referral from specialists. We randomly assigned participants to either the intervention (smoked cannabis, once daily for three days) or control (identical placebo cigarettes, once daily for three days). Each participant was assessed daily before and after treatment. After a washout interval of 11 days, participants crossed over to the op posite group. Our primary outcome was change in spasticity as measured by patient score on the modified Ashworth scale. Our secondary outcomes included patients' perception of pain (as measured using a visual analogue scale), a timed walk and changes in cognitive function (as measured by patient performance on the Paced Auditory Serial Addition Test), in addition to ratings of fatigue.Results: Thirty-seven participants were randomized at the start of the study, 30 of whom completed the trial. Treatment with smoked cannabis resulted in a reduction in patient scores on the modified Ashworth scale by an average of 2.74 points more than placebo (p < 0.0001). In addition, treatment reduced pain scores on a visual analogue scale by an average of 5.28 points more than placebo (p = 0.008). Scores for the timed walk did not differ significantly between treatment and placebo (p = 0.2). Scores on the Paced Auditory Serial Addition Test decreased by 8.67 points more with treatment than with placebo (p = 0.003). No serious adverse events occurred during the trial. Interpretation:Smoked cannabis was superior to placebo in symptom and pain reduction in participants with treatment-resistant spasticity. Future studies should examine whether different doses can result in similar beneficial effects with less cognitive impact. Abstract

show abstract

Section: Methodsmentioning

confidence: 99%

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

Corey–Bloom

Wolfson

Gamst

et al. 2012

CMAJ

177

145

View full text Add to dashboard Cite

show abstract

“…Mentored by Hank Pennypacker, Maria was trained in the strong EAB tradition at UF and worked on a variety of research projects, including those involving self-injury (Ruiz, 1985), stimulus overselectivity (Ruiz, 1983b), fluency-based instruction (Ruiz, 1983a), and contingency contracting in the treatment of individuals with drug abuse (Boudin et al, 1977). Maria continued to sharpen her EAB skills and expanded further into behavioral pharmacology in a postdoctoral position with Joe Brady at Johns Hopkins University (Foltin et al, 1986).…”

mentioning

confidence: 99%